Saturday 17 October 2026
Export EW’s income statement to Excel — free account
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
86.60
1.50
−1.70%
Follow EW
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
51.99 | 42.37 | 46.33 | 33.38 |
+8 more quarters Free account |
P/S ratio |
8.01 | 7.36 | 8.22 | 7.73 | |
P/FCF ratio |
37.15 | 43.78 | 38.20 | 58.73 | |
P/Operating CF |
79.98 | 1,058.96 | 110.57 | 79.26 | |
P/B ratio |
4.86 | 4.49 | 4.82 | 4.46 | |
Price to Tangible BV |
7.05 | 6.37 | 6.70 | 6.22 | |
EV/Sales |
7.54 | 6.97 | 7.72 | 7.28 | |
EV/EBITDA |
30.40 | 29.12 | 32.96 | 27.07 | |
EV/Operating CF |
28.53 | 32.32 | 29.35 | 42.12 | |
EV/FCF |
34.97 | 41.44 | 35.88 | 55.32 | |
Quick Ratio |
3.45 | 3.30 | 2.83 | 2.98 | |
Current Ratio |
4.52 | 4.42 | 3.72 | 4.00 | |
Net Debt/EBITDA |
(6.57) | (5.93) | (18.72) | (9.37) | |
Debt/Assets |
4.32% | 4.49% | 4.37% | 4.51% | |
Debt/Equity |
0.06 | 0.06 | 0.06 | 0.06 | |
Asset Turnover |
0.48 | 0.48 | 0.45 | 0.45 | |
Operating CF/Net income |
2.69 | 0.12 | 4.94 | 1.97 | |
Capex/Depreciation |
(1.57) | (1.59) | (2.28) | (1.47) | |
Research and Development Expense of Revenue |
16.02% | 15.97% | 17.06% | 18.07% | |
Selling, General and Administrative Expense of Revenue |
32.23% | 31.68% | 38.41% | 33.13% | |
Intangible Assets out of Total Assets |
0.24 | 0.23 | 0.21 | 0.22 | |
Share Based Compensation of Revenue |
2.42% | 2.75% | 2.50% | 2.65% | |
Graham Net Nets |
0.07 | 0.07 | 0.07 | 0.07 | |
Graham Number |
26.99 | 27.54 | 27.05 | 30.25 | |
Earnings Yield |
1.92% | 2.36% | 2.16% | 3.00% | |
Free Cash Flow Yield |
2.69% | 2.28% | 2.62% | 1.70% | |
Revenue per Share |
3.02 | 2.85 | 2.68 | 2.66 | |
Operating CF per Share |
1.13 | 0.08 | 0.77 | 0.98 | |
Capex per Share |
(0.12) | (0.11) | (0.17) | (0.10) | |
Free Cash Flow per Share |
1.01 | (0.04) | 0.60 | 0.88 | |
Cash per Share |
7.38 | 6.34 | 7.23 | 6.57 | |
Shareholders Equity per Share |
18.61 | 17.83 | 17.68 | 17.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.61 | 17.83 | 17.68 | 17.45 | |
Free Cash Flow |
585.00 | (21.10) | 353.50 | 516.20 | |
Working Capital |
5,311.00 | 4,819.70 | 4,925.20 | 4,770.90 | |
Capital Expenditures |
(66.90) | (64.90) | (97.40) | (57.50) | |
Net Current Asset Value |
3,676.70 | 3,235.00 | 3,379.30 | 3,291.70 | |
EV/EBIT |
33.88 | 32.60 | 37.04 | 30.04 | |
Capex to Sales |
0.04 | 0.04 | 0.06 | 0.04 | |
Price to Operating Income |
35.98 | 34.43 | 39.44 | 31.89 | |
| Other line items | |||||
Average Receivables |
929.15 | 862.45 | 819.75 | 852.15 | |
Average Payables |
186.30 | 176.75 | 212.45 | 168.90 | |
Average Inventory |
1,136.45 | 1,116.45 | 1,106.45 | 1,122.55 | |
Average Assets |
13,677.90 | 13,171.75 | 13,376.25 | 13,121.70 | |
Average Common Equity |
10,665.70 | 10,259.55 | 10,200.25 | 9,908.20 |
Columns are period end dates